5 reasons why no one has built a better EpiPen
(By Meghana Keshavan for STAT) Boston mom Denise Clark has been buying EpiPens annually for the past 16 years, ever
Read More
Part D/Prescription Drugs
Get Set for 2017 Medicare Changes
Open Enrollment is hurtling toward us, so now’s a good time to start thinking about the decisions you’ll need to
Read MoreMeet the man who’s the federal government’s pot dealer
(By Andrew Joseph for STAT) Mahmoud ElSohly oversees acres of marijuana plants in the deep south, a swath of the
Read MoreDoctors Without Borders urges Gilead to rethink its hepatitis C strategy in Ukraine
(By Ed Silverman for STAT) The latest battle over access to medicines is taking place in Ukraine, where Doctors Without
Read MoreEpiPen maker under investigation for antitrust violations in New York
(By Ike Swetlitz for STAT) New York Attorney General Eric T. Schneiderman is investigating Mylan Pharmaceuticals for potential antitrust violations involving
Read MoreGene therapy for sickle cell moves closer as scientists clear unexpected obstacle
(By Sharon Begley for STAT) Researchers have cleared the last scientific hurdle to a clinical trial of gene therapy1 to cure sickle
Read MoreSaline Nose Spray Might Help Tame Severe Nosebleeds
(By Nancy Shute for NPR) Saline nose spray is becoming increasingly popular as a treatment for allergies and sinus problems.
Read MoreThe drug pricing crusader at the center of one of the nastiest fights of the election season
(By Rebecca Robbins for STAT) LOS ANGELES — There’s nobody the drug companies are spending more to fight than Michael
Read MoreHHS accelerates development of mRNA-based Zika vaccine
(Source – www.hhs.gov) The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response
Read MoreAllergan CEO promises to limit price hikes on drugs in a bid to rebuild the ‘social contract’
(By Ed Silverman for STAT) Seeking to deflect harsh criticism of the pharmaceutical industry, one chief executive officer — Allergan’s
Read More